Skip to content

Omeros

US · OMER #3062 by market cap Listed 1970
13.21 -0.80 -5.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio -24.67 Cheap vs history 9th percentile
5-year average -6.00
P/E ratio 10.11 Expensive vs history 90th percentile
5-year average -4.68 · forward 16.91 · #35 of 75 in Biotechnology
P/S ratio 32.95 Expensive vs history 91st percentile
5-year average 6.12 · forward 7.26 · #243 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Omeros (OMER) 983.66M 8.52 -10.94 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value19.57 Economic moatNarrow UncertaintyVery High

Trading 48.1% below Morningstar's fair value estimate.

Fair value

Omeros Corp receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 11% discount to our quantitative fair value estimate of $19.57 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet strengthens our valuation estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its long term debt to assets ratio of 0.4, which falls in the top 10% compared with peers globally. The firm has a high level of long-term debt relative to its asset base, which can signal significant investment in the business or a pending merger. In either case, it may suggest future growth in cash flows. We believe this is a sign that shares could be cheap.

Conversely, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of -4.2%, for example, falls in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:33 · For reference only, not investment advice and not tailored to your situation.

Omeros discussion 0 comments

Add a comment